Radiotherapy in the Management of Localized Primary Cutaneous B-Cell Lymphoma.

August 2012

Itai Pashtan, Peter M. Mauch, Yu-Hui Chen, David M. Dorfman, Barbara Silver, Andrea K. Ng

Corresponding author: Itai Pashtan, MD, Department of Radiation Oncology, 

Brigham and Women's Hospital, 75 Francis Street, ASB1-L2, Boston, MA 02115

, USA. Tel: +1-617-732-6231; Fax: +1-617-975-0932; E-mail: ipashtan@partners.org

Keywords

Primary cutaneous B-cell lymphoma, prognosis, radiation, dose, local control

Abstract

The optimal therapy and radiation dose for patients with localized primary cutaneous B-cell lymphoma (PCBCL) are unknown. We retrospectively identified 23 patients with localized (T1-T2) PCBCL treated with definitive radiation to doses ranging from 30–44 Gy (median, 36 Gy). With median follow-up of 4.8 years, the 5-year overall survival rate was 100%, the relapse-free survival rate was 71% (95% CI, 46-86%) and there were no local recurrences, suggesting that radiotherapy to a dose of 30 Gy may be sufficient for cure.

Informahealth